Baby Bunting started FY23 with a margin downgrade
Baby Bunting (ASX:BBN) shareholders punished the company today for revealing a hit to its gross margins. Despite recording sales growth, it has not been enough to outweigh the impact of increased freight and forex costs.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
Baby Bunting hit by rising costs
Baby Bunting has been relatively resilient to the pandemic as people have continued to have babies. But at today’s AGM, the company revealed its gross profit margin in the first quarter of FY23 fell from 38.7% to 37.2% in 12 months. As a consequence, BBN shares plunged over 20% this morning.
Baby Bunting (ASX:BBN) share price chart (Graph: TradingView)
The company blamed unrecovered cost increases, particularly freight charges and forex movements., as well as the commencement of its loyalty program and reduced demand in the play gear department.
The company told shareholders that total sales growth was 12% and comparable store sales growth was 7.6%. It also still planned to open a total of 8 stores in FY23, having opened 3 so far. But it declined to provide guidance for the full year.
A rough AGM
Baby Bunting revealed the bad news at its AGM this morning. It reminded shareholders about its achievements in FY22, including achieving sales of over $500m for the first time, and it grew its net profit (which was $29.6m) despite its expansion into New Zealand.
Looking forward, BBN told shareholders its current addressable market was $2.5bn and could grow to $3.5bn with its new Baby Bunting Marketplace.
This did not stop Baby Bunting shares from falling as its reputation as a safe-haven to external economic pressures is at risk, if it is not gone already.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY26
Recent Posts
Imricor Medical (ASX:IMR) FDA Approval Ignites Shares, but the Real Test Starts Now
FDA Approval Is a Big Win, Not the Finish Line Imricor Medical (ASX:IMR) received FDA clearance for its Vision-MR diagnostic…
How Nuclear Energy Became the World’s Most Feared Energy Source
Why Nuclear Energy Still Scares Us and What Really Went Wrong Many investors may remember periods when nuclear energy captured…
Dateline Resources (ASX:DTR) From 60c Highs to Hard Lessons
A Rare Earth Story the Market Loved Then Questioned For investors who have followed Dateline Resources (ASX:DTR), the past year…